Literature DB >> 7359121

Clonidine: attenuation of sedative action by facilitated central noradrenergic neurotransmission.

U Strömbom, T H Svensson.   

Abstract

Administration of clonidine, 0.05 mg/kg i.p. to mice 30 min before trial significantly depressed the exploration of a Y-maze. This effect was completely antagonized by 1-amphetamine, 0.75 mg/kg i.p., given 10 min before trial, which by itself did not change the behaviour studied. The clonidine-induced behavioural depression also appeared reduced after pretreatment with desipramine (10 mg/kg i.p., 30 min before clonidine) which, like l-amphetamine, by itself was inactive. The above treatment with clonidine significantly reduced the accumulation of dopa after inhibition of central aromatic L-amino acid decarboxylase both in the noradrenaline (NA) rich neocortex and the dopamine-rich neocortex and the dopamine-rich corpus striatum, whereas the dopa accumulation in the limbic brain regions was not significantly affected. l-Amphetamine, 0.75 mg/kg i.p., did not by itself significantly affect the dopa accumulation, but reduced the clonidine-induced effects. The results are compatible with the notion that the depression of exploratory behaviour by clonidine is related to impaired central NA-neurotransmission and rule out the possibility that it is due to activation of central post-synaptic NA-(alpha-)-receptors.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7359121     DOI: 10.1007/bf01256637

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  40 in total

1.  Noradrenergic neurons of the locus coeruleus: inhibition by epinephrine and activation by the alpha-antagonist piperoxane.

Authors:  J M Cedarbaum; G K Aghajanian
Journal:  Brain Res       Date:  1976-08-13       Impact factor: 3.252

2.  Inhibition of both noradrenergic and serotonergic neurons in brain by the alpha-adrenergic agonist clonidine.

Authors:  T H Svensson; B S Bunney; G K Aghajanian
Journal:  Brain Res       Date:  1975-07-11       Impact factor: 3.252

3.  Discontinuation of chronic clonidine treatment: evidence for facilitated brain noradrenergic neurotransmission.

Authors:  T H Svensson; U Strömbom
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-08       Impact factor: 3.000

4.  Involvement of alpha-receptors in clonidine-induced inhibition of transmitter release from central monoamine neurones.

Authors:  K Starke; H Montel
Journal:  Neuropharmacology       Date:  1973-11       Impact factor: 5.250

5.  Evidence for a central noradrenaline receptor stimulation by clonidine.

Authors:  N E Andén; H Corrodi; K Fuxe; B Hökfelt; T Hökfelt; C Rydin; T Svensson
Journal:  Life Sci       Date:  1970-05-01       Impact factor: 5.037

6.  Dopamine and noradrenaline receptor stimulation: reversal of reserpine-induced suppression of motor activity.

Authors:  N E Andén; U Strömbom; T H Svensson
Journal:  Psychopharmacologia       Date:  1973

7.  Effect of ethanol on the hydroxylation of tyrosine and tryptophan in rat brain in vivo.

Authors:  A Carlsson; M Lindqvist
Journal:  J Pharm Pharmacol       Date:  1973-06       Impact factor: 3.765

8.  Behavioural and biochemical effects of 2-(2,6-dichlorophenylamino)-2-imidazoline hydrochloride (St 155) on the central nervous system.

Authors:  R Laverty; K M Taylor
Journal:  Br J Pharmacol       Date:  1969-02       Impact factor: 8.739

9.  Locomotor stimulation by L-dopa: relative importance of noradrenaline receptor activation.

Authors:  N E Andén; U Strömbom; T H Svensson
Journal:  Psychopharmacology (Berl)       Date:  1977-11-15       Impact factor: 4.530

10.  Clonidine-induced locomotor hyperactivity in rats. The role of central postsynaptic alpha-adrenoceptors.

Authors:  I Zebrowska-Lupina; E Przegalinski; M Sloniec; Z Kleinrok
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-04       Impact factor: 3.000

View more
  9 in total

1.  A study of the possible influence of central 5-HT function on clonidine-induced hypoactivity responses in mice.

Authors:  D J Heal; J Philpot
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

2.  Locomotor activity of rats after stimulation of the nucleus locus coeruleus region or after lesion of the dorsal noradrenergic bundle: effects of clonidine, prazosin and yohimbine.

Authors:  L Velley; E Kempf; B Cardo
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

3.  Control of behaviour and brain noradrenaline neurons by peripheral blood volume receptors.

Authors:  B Persson; T H Svensson
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

4.  Effects of trazodone treatment on alpha-2 adrenoceptor function in depressed patients.

Authors:  L H Price; D S Charney; G R Heninger
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

5.  Sex-related differences in central adrenergic function and responsiveness to repeated administration of desipramine or electroconvulsive shock.

Authors:  D J Heal; L M Bristow; E M Hurst; J M Elliott; W R Buckett
Journal:  Br J Pharmacol       Date:  1989-05       Impact factor: 8.739

6.  Clonidine-induced sedation in rats: evidence for mediation by postsynaptic alpha 2-adrenoreceptors.

Authors:  C Spyraki; H C Fibiger
Journal:  J Neural Transm       Date:  1982       Impact factor: 3.575

7.  Spinal modulation of acoustic startle: opposite effects of clonidine and d-amphetamine.

Authors:  M Davis; D I Astrachan
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

8.  Noradrenergic hyperactivity in hippocampus after partial denervation: pharmacological, behavioral, and electrophysiological studies.

Authors:  C Dyon-Laurent; A Hervé; S J Sara
Journal:  Exp Brain Res       Date:  1994       Impact factor: 1.972

9.  Modulation of rat brain alpha-adrenoreceptor populations four weeks after stimulation of the nucleus locus coeruleus.

Authors:  L Velley; B Cardo; J Bockaert
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.